FLT3 mutation testing

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%

Pediatric APL patients with FLT3 mutations had lower 5-year overall survival (62%) compared to FLT3 wild-type patients (68%), with FLT3 mutation status identified as an independent prognostic factor f

Effect: decline; 62% vs 68%